PND55 - A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY- COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY ...
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.2021
https://www.valueinhealthjournal.com/article/S1098-3015(18)35323-3/fulltext
Title :
PND55 - A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY- COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35323-3&doi=10.1016/j.jval.2018.09.2021
First page :
Section Title :
Open access? :
No
Section Order :
1377